Matthew Korenberg

2019

In 2019, Matthew Korenberg earned a total compensation of $3.6M as Executive Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 34% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$186,667
Option Awards$1,445,555
Salary$466,667
Stock Awards$1,466,580
Other$5,734
Total$3,571,203

Korenberg received $1.5M in stock awards, accounting for 41% of the total pay in 2019.

Korenberg also received $186.7K in non-equity incentive plan, $1.4M in option awards, $466.7K in salary and $5.7K in other compensation.

Rankings

In 2019, Matthew Korenberg's compensation ranked 3,394th out of 13,971 executives tracked by ExecPay. In other words, Korenberg earned more than 75.7% of executives.

ClassificationRankingPercentile
All
3,394
out of 13,971
76th
Division
Manufacturing
1,232
out of 5,701
78th
Major group
Chemicals And Allied Products
420
out of 2,200
81st
Industry group
Drugs
348
out of 1,886
82nd
Industry
Pharmaceutical Preparations
261
out of 1,398
81st

Pay ratio

Matthew Korenberg's Pay$3,571,203
Median Employee's Pay$109,795
Pay Ratio

33

to 1

In 2019, the annual total compensation of Matthew Korenberg was $3,571,203.

The annual total compensation of the median employee at Ligand Pharmaceuticals was $109,795.

The ratio of Matthew Korenberg's pay to the pay of median employee was therefore 33 to one.

Source: SEC filing on November 12, 2020.

Korenberg's colleagues

We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2019.

2019

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2019

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2019

Charles Berkman

Ligand Pharmaceuticals

General Counsel

News

You may also like